Literature DB >> 15251517

Diagnosis and management of diabetes insipidus during pregnancy.

J A Durr1, M D Lindheimer.   

Abstract

OBJECTIVE: To provide an overview of diagnostic and treatment strategies in pregnant patients with diabetes insipidus (DI).
METHODS: We review the changes in osmoregulation during normal pregnancy, characterize the various types of DI that can occur during pregnancy, and discuss the recommended management.
RESULTS: The incidence of DI is 2 to 4 cases per 100,000 gestations. Central DI can precede pregnancy or manifest initially during gestation. With preexistent central DI, pregnancy usually aggravates the disorder, and the requirements for antidiuretic hormone (ADH) usually increase. Such an effect is less likely to be noted in ADH-independent nephrogenic forms of DI. Currently, the major type of DI associated with pregnancy is a transient syndrome that is resistant to arginine vasopressin (AVP) but responsive to desmopressin (dDAVP); such cases of DI are often associated with liver abnormalities or preeclampsia. This syndrome is explained by excess vasopressinase, a placental enzyme which degrades AVP but not dDAVP. A transient recurrent type of DI can occur during gestation in patients with limited ADH-secreting capacity and is responsive to both AVP and dDAVP. Latent central DI manifesting after complicated delivery and transient nephrogenic DI, resistant to both AVP and dDAVP, have also been reported.
CONCLUSION: The differential diagnosis of polyuric and polydipsic states during pregnancy is broad, and precise diagnosis may be difficult. The use of dDAVP to treat DI during gestation has proved effective and safe for both the mother and the fetus.

Entities:  

Year:  1996        PMID: 15251517     DOI: 10.4158/EP.2.5.353

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  5 in total

Review 1.  Transient gestational diabetes insipidus diagnosed in successive pregnancies: review of pathophysiology, diagnosis, treatment, and management of delivery.

Authors:  Ibrahim Kalelioglu; Ayse Kubat Uzum; Alkan Yildirim; Tulay Ozkan; Funda Gungor; Recep Has
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 2.  Desmopressin therapy in children and adults: pharmacological considerations and clinical implications.

Authors:  Xinyi Chin; Shao Wei Teo; Soo Ting Lim; Yong Hong Ng; How Chuan Han; Fabian Yap
Journal:  Eur J Clin Pharmacol       Date:  2022-02-23       Impact factor: 2.953

Review 3.  G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.

Authors:  Kirk P Conrad
Journal:  Hum Reprod Update       Date:  2016-07-06       Impact factor: 15.610

4.  Transient diabetes insipidus in a post-partum woman with pre-eclampsia associated with residual placental vasopressinase activity.

Authors:  Natassia Rodrigo; Samantha Hocking
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-05-21

Review 5.  Management of Hypopituitarism.

Authors:  Krystallenia I Alexandraki; AshleyB Grossman
Journal:  J Clin Med       Date:  2019-12-05       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.